VIKAS LIFECARE LIMITED — Capital/Financing Update 2021

Jul 22, 2021

==> picture [490 x 103] intentionally omitted <==

Date: July 21, 2021

Listing Department National Stock Exchange of India Limited Exchange Plaza Bandra-Kurta Complex, Bandra (E), Mumbai 400 051

Subject : Reply to the clarification sought on proposal to acquire M/s Hydrolina Biotech Private Limited.

Dear Madam/Sir,

With reference to clarification sought by your good office with regard to the captioned subject, we wish to clarify the below points:

1. Name and brief details of the Target Entity:

Name : Hydrolina Biotech Private Limited CIN : U15440TN1999PTC042911 Authorized Capital : Rs. 5,00,00,000 Paid up Capital : Rs. 4,10,96,210 Turnover : Company is in NCLT and we are proposing to submit resolution plan to take over the control and management of the company, if approved by the Company

Brief Background:

Hydrolina Biotech is engaged in nutraceuticals-derived from natural resources and started manufacturing and exporting "Vitalinaa" – Spirulina dried Powder, Tablets & Capsules, and sensing the huge opportunity in "Lycopene" later decided to enter into it, initiated R&D, for extraction of Lycopene for commercial purpose and had obtained 2 two patent in this regard.

Approved and financially supported by the Department of Biotechnology (DBT) and Technology Development Board (TDB), Ministry of Science &Technology, Govt. of India, the Company hasit'sstate of-the-Art R&D facility, duty recognized by DSIR (Department of Scientific &

==> picture [462 x 25] intentionally omitted <==

==> picture [490 x 103] intentionally omitted <==

industrial Research) under Ministry of Science & Technology, New Delhi, Govt. of India and its manufacturing plant in Tamilnadu. Its lycopene manufacturing unit is in full ready status, with all necessary approvals, as such production can be commenced immediately to tap the demand lycopene across the globe which is growing at rapid pace.

2. Whether the acquisition would fall within related party transactions and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at ‘arm’s length’ :

No, its not a related party transaction.

3. Cost of Acquisition or the price at which the shares are acquired ;

4. Nature of consideration- whether cash consideration or share swap and details of the same;

5. Percentage of shareholding / control acquired and / or number of shares acquired;

Reply for Query No. 3, 4 & 5

The Target Company is in NCLT and we are proposing to submit resolution plan to take over thecontrol and management of the company, if approved by the NCLT. At present Board of Directors of Vikas Lifecare Limited approved for initiating the necessary process under Insolvency and Bankruptcy Code, 2016. Cost of acquisition, mode of consideration, Percentage of shareholding / control acquired and / or number of shares acquired could not be submitted/informed at this stage.

Trust your honored self ‘ll find this submission satisfactory and in order. Kindly take this on record and oblige. In case any further clarification/information is required, it shall be our pleasure to provide the same.

Thanking you,

Yours Faithfully, For Vikas Lifecare Limited

==> picture [126 x 75] intentionally omitted <==

Monika Soni Company Secretary

==> picture [462 x 25] intentionally omitted <==